AstraZeneca’s (AZN) “Hold” Rating Reiterated at Shore Capital

Shore Capital reiterated their hold rating on shares of AstraZeneca (LON:AZN) in a report released on Monday morning.

A number of other equities research analysts also recently commented on AZN. Barclays reiterated an overweight rating and issued a GBX 5,500 ($74.02) price objective on shares of AstraZeneca in a report on Monday, August 7th. set a GBX 4,100 ($55.18) price objective on AstraZeneca and gave the company a sell rating in a report on Tuesday, August 8th. Investec upgraded AstraZeneca from a hold rating to a buy rating and dropped their price objective for the company from GBX 5,000 ($67.29) to GBX 4,900 ($65.95) in a report on Wednesday, August 9th. J P Morgan Chase & Co set a GBX 4,200 ($56.53) price objective on AstraZeneca and gave the company a neutral rating in a report on Wednesday, August 9th. Finally, Goldman Sachs Group set a GBX 3,900 ($52.49) price objective on AstraZeneca and gave the company a sell rating in a report on Friday, August 18th. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the company. AstraZeneca presently has a consensus rating of Hold and a consensus price target of GBX 5,169 ($69.57).

AstraZeneca (AZN) opened at GBX 4,704 ($63.31) on Monday. AstraZeneca has a twelve month low of GBX 3,996 ($53.78) and a twelve month high of GBX 5,520 ($74.29).

TRADEMARK VIOLATION NOTICE: This article was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://www.com-unik.info/2017/12/07/astrazenecas-azn-hold-rating-reiterated-at-shore-capital.html.

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (LON:AZN)

What are top analysts saying about AstraZeneca PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AstraZeneca PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit